Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ladostigil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 19/20 | 0.87 |
| ▸ | MAOA | P21397 | 2/20 | 0.87 |
| ▸ | MAOB | P27338 | 2/20 | 0.87 |
| ▸ | BCHE | P06276 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ladostigil SCHEMBL30579760 | 1.00 | ACHE (0.87) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL3893996 | 0.93 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL678895 | 0.93 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL3301711 | 0.93 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13853627 | 0.88 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13853626 | 0.85 | ACHE (0.84) | ACHEMAOAMAOBBCHE | |
| SCHEMBL12043626 | 0.85 | ACHE (0.84) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3895981 | 0.84 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13449663 | 0.84 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3895985 | 0.84 | ACHE (0.98) | ACHEMAOAMAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719474-A1 | METHOD OF TREATING FIBROTIC-RELATED CONDITION | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024252394-A1 | METHOD OF TREATING FIBROTIC-RELATED CONDITION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024238387-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO., LTD. (KR) | 2024-11-21 | — | — | WO | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2024036005-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO., LTD. (KR) | 2024-02-15 | — | — | WO | disclosed |
| US-20230384333-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-30 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| US-20070203232-A1 | Propargylated aminoindans, processes for preparation, and uses thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
| WO-2007061717-A2 | METHODS FOR ISOLATING PROPARGYLATED AMINOINDANS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112217-A1 | Methods for isolating propargylated aminoindans | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| WO-2006120577-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF ENANTIOMERIC INDANYLAMINE DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006091836-A9 | FORMULATIONS OF LADOSTIGIL TARTRATE | TEVA PHARMA (IL) | 2006-10-26 | — | — | WO | disclosed |
| US-20060199974-A1 | propynylaminoindans including alkoxy or alkylcarbamates derivatives, prepared by reduction of indanones in the presence of hydrogenation catalysts to form indanols and reacting the indanols with propargylamine under nucleophilic substitution to form drugs for the treatment of nervous system disorders | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-09-07 | — | — | US | disclosed |
| WO-2006091656-A1 | CRYSTALS OF LADOSTIGIL TARTRATE, METHODS OF PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091836-A1 | FORMULATIONS OF LADOSTIGIL TARTRATE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189685-A1 | Formulations of ladostigil tartrate | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (40%) (IL) | 2006-08-24 | — | — | US | disclosed |
| US-20060189819-A1 | Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ACHE 1641/4885MAOA 2331/4885MAOB 2721/4885 |
| US-20060189819-A1 | Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof | LIPA, MTTP, LPXN | ACHE 143/4885MAOA 2360/4885MAOB 3315/4885 |
| US-20070112217-A1 | Methods for isolating propargylated aminoindans | AAAS, AGT, ARL1 | ACHE 1083/4885MAOA 1000/4885MAOB 1418/4885 |
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | BCHE, ACHE, CHAT | ACHE 2/4885MAOA 14/4885MAOB 8/4885 |
| US-20060199974-A1 | propynylaminoindans including alkoxy or alkylcarbamates derivatives, prepared by reduction of indanones in the presence of hydrogenation catalysts to form indanols and reacting the indanols with propargylamine under nucleophilic substitution to form drugs for the treatment of nervous system disorders | ICMT, INMT, PNMT | ACHE 23/4885MAOA 537/4885MAOB 407/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ACHE 403/4885MAOA 164/4885MAOB 23/4885 |
| US-20060189685-A1 | Formulations of ladostigil tartrate | LIPG, LIPA, LPL | ACHE 62/4885MAOA 2616/4885MAOB 2753/4885 |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | IL2, PBK, IL2RA | ACHE 99/4885MAOA 1708/4885MAOB 1581/4885 |
| US-20070203232-A1 | Propargylated aminoindans, processes for preparation, and uses thereof | PRMT3, PRMT1, PNMT | ACHE 76/4885MAOA 511/4885MAOB 510/4885 |
| US-20230384333-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | HTR4, HTR6, HTR1A | ACHE 649/4885MAOA 216/4885MAOB 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.